SUZ12 and cancer: While these tumors might be insensitive to EZH2 inhibitors, a correlation between higher expression of PRC2 and good prognosis might be of interest as it might suggest a possible sensitivity of these tumors to inhibitors of KDM6 that demethylate H3K27me3 [124], or of active chromatin components, such as those previously reported for SUZ12 inactivating mutations that sensitize several cancer types to inhibitors of Bromodomain and Extra-Terminal motif (BET) proteins, a family of proteins that counteract gene silencing with a chromatin activation function [125].